Aaron Kantoff - 05 Sep 2025 Form 4 Insider Report for Tourmaline Bio, Inc. (TRML)

Role
Director
Signature
/s/ Brad Middlekauff, Attorney-in-Fact
Issuer symbol
TRML
Transactions as of
05 Sep 2025
Net transactions value
+$99,526
Form type
4
Filing time
09 Sep 2025, 18:00:06 UTC
Previous filing
18 Jun 2025
Next filing
24 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
KANTOFF AARON Director C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK /s/ Brad Middlekauff, Attorney-in-Fact 09 Sep 2025 0001862734

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRML Common Stock Options Exercise $4,926 +37,890 +83% $0.1300 83,281 05 Sep 2025 Direct
transaction TRML Common Stock Options Exercise $94,600 +10,000 +12% $9.46 93,281 05 Sep 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRML Stock Option (Right to Buy) Options Exercise $0 -37,890 -100% $0.000000 0 05 Sep 2025 Common Stock 37,890 $0.1300 Direct F1
transaction TRML Stock Option (Right to Buy) Options Exercise $0 -10,000 -100% $0.000000 0 05 Sep 2025 Common Stock 10,000 $9.46 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option are fully vested and immediately exercisable.